Response-related predictors of survival in CML

• Verfasst von: Hanfstein, Benjamin [VerfasserIn]
• Verfasst von: Müller, Martin Christian [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Titel: Response-related predictors of survival in CML
• Verf.angabe: Benjamin Hanfstein, Martin C. Müller, Andreas Hochhaus
• Umfang: 13 S.
• Fussnoten: Gesehen am 13.11.2017
• Titel Quelle: Enthalten in: Annals of hematology
• Jahr Quelle: 2015
• Band/Heft Quelle: 94(2015), Supplement 2, S. S227-S239
• ISSN Quelle: 1432-0584
• DOI: doi:10.1007/s00277-015-2327-x
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 156528853X

Abstract

The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as early as 3 months on treatment allows a prognostic stratification of a patient’s individual risk. With competing TKI regimens available, a timely switch of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI and for second-line TKI treatment as well.